BlackRock’s Theriva Biologics TOVX Stock Holding History

BlackRock’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.88K	Hold	7,504	–	–	﹤0.01%	5539
2026 Q1	$1.47K	Hold	7,504	–	–	﹤0.01%	5537
2025 Q4	$1.58K	Sell	7,504 -2	-0%	-$1	﹤0.01%	5403
2025 Q3	$3.04K	Sell	7,506 -62	-0.8%	-$27	﹤0.01%	5303
2025 Q2	$3.28K	Hold	7,568	–	–	﹤0.01%	5298
2025 Q1	$8.32K	Hold	7,568	–	–	﹤0.01%	5193
2024 Q4	$13.2K	Hold	7,568	–	–	﹤0.01%	5152
2024 Q3	$10.4K	Buy	7,568 +1	+0%	+$5	﹤0.01%	4981
2024 Q2	$44.7K	Hold	7,567	–	–	﹤0.01%	4885
2024 Q1	$88.7K	Sell	7,567 -35	-0.5%	-$410	﹤0.01%	4761
2023 Q4	$81.7K	Sell	7,602 -5	-0.1%	-$62	﹤0.01%	4865
2023 Q3	$103K	Hold	7,607	–	–	﹤0.01%	4839
2023 Q2	$190K	Hold	7,607	–	–	﹤0.01%	4751
2023 Q1	$133K	Hold	7,607	–	–	﹤0.01%	4894
2022 Q4	$86.5K	Hold	7,607	–	–	﹤0.01%	5088
2022 Q3	$187K	Buy	7,607 +64	+0.8%	+$2.46K	﹤0.01%	4996
2022 Q2	$402K	Hold	7,543	–	–	﹤0.01%	4843
2022 Q1	$538K	Hold	7,543	–	–	﹤0.01%	4846
2021 Q4	$513K	Buy	7,543 +35	+0.5%	+$3.3K	﹤0.01%	4861
2021 Q3	$863K	Hold	7,508	–	–	﹤0.01%	4597
2021 Q2	$1.13M	Sell	7,508 -1,885	-20%	-$270K	﹤0.01%	4479
2021 Q1	$1.6M	Buy	9,393 +9,240	+6,039%	+$1.83M	﹤0.01%	4363
2020 Q4	$14K	Hold	153	–	–	﹤0.01%	4816
2020 Q3	$19K	Hold	153	–	–	﹤0.01%	4724
2020 Q2	$20K	Hold	153	–	–	﹤0.01%	4703
2020 Q1	$12K	Hold	153	–	–	﹤0.01%	4690
2019 Q4	$20K	Hold	153	–	–	﹤0.01%	4660
2019 Q3	$17K	Hold	153	–	–	﹤0.01%	4667
2019 Q2	$21K	Hold	153	–	–	﹤0.01%	4683
2019 Q1	$26K	Hold	153	–	–	﹤0.01%	4564
2018 Q4	$22K	Hold	153	–	–	﹤0.01%	4574
2018 Q3	$100K	Hold	153	–	–	﹤0.01%	4454
2018 Q2	$320K	Buy	153 +1	+0.7%	+$2.3K	﹤0.01%	4211
2018 Q1	$425K	Sell	152 -1	-0.7%	-$3.8K	﹤0.01%	4078
2017 Q4	$681K	Hold	153	–	–	﹤0.01%	3988
2017 Q3	$1.25M	Buy	153 +20	+15%	+$116K	﹤0.01%	3842
2017 Q2	$658K	Sell	133 -505	-79%	-$2.52M	﹤0.01%	3947
2017 Q1	$3.52M	Buy	+638	New	+$4.45M	﹤0.01%	3490
2016 Q4	–	Hold	0	–	–	–	3651
2016 Q3	–	Hold	0	–	–	–	3513
2016 Q2	–	Hold	0	–	–	–	3522

Other funds holding TOVX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

BlackRock's TOVX Position: Q2 2026 in Review

BlackRock held its Theriva Biologics (TOVX) position steady in Q2 2026 at 7,504 shares worth $1.88K. The position accounts for ﹤0.01% of the portfolio, ranked #5539.

BlackRock first reported a position in TOVX in Q1 2017 and has held it in 38 quarters since. The position peaked at $3.52M in Q1 2017. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

BlackRock held 7,504 shares of Theriva Biologics worth $1.88K as of Q2 2026.
BlackRock left its Theriva Biologics share count unchanged in Q2 2026.
Theriva Biologics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5539 holding.
BlackRock first reported a position in Theriva Biologics in Q1 2017 and has held it in 38 quarters since.
BlackRock's Theriva Biologics position peaked at $3.52M in Q1 2017.
26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.